Evaluation of Her2 Positivity in Gastric Cancer Using Two Different Methods: A Prospective Study
Öz
ABSTRACT
BACKGROUND: Stomach cancer is one of the most common gastrointestinal tract tumors. Its incidence varies according to ethnic group, geographical conditions, dietary habits, economic status, lifestyle and Helicobacter pylori prevalence. Genetic factors play a major role in the pathogenesis of gastric cancer, and the human epidermal growth factor receptor 2 Her2/neu (c-erb B2) gene is one of these factors.
METHOD: The objective of this study is to compare any correlation between the amplification level of Her2/neu gene in gastric cancer by real-time polymerase chain reaction (RT-PCR) with Her2 protein overexpression obtained from the same tissue and studied with immunohistochemisry (IHC), and in the event of positivity, to determine its relationshipwith other known prognostic factors such as age, gender, stage, tumor localization and histological type.
RESULTS: IHC results indicated Her2 overexpression in 5 (10%) patients and RT-PCRindicated amplification also in 5 (10%) patients. There was no significant correlation between the results determined by the two methods (p> 0.05). Additionally, no statistically significant difference was detected between prognostic factors and gene expressions in tumor tissues (p> 0.05).
CONCLUSION: Her2 gene amplification and protein overexpression can potentially contribute to tumor development. Further studies are needed to evaluate false negativity, investigate patient survival in terms of its contribution to prognosis, and corroborate our hypothesis.
Anahtar Kelimeler
Gastric cancer, Her2 (c-erb B2), RT-PCR, IHC
Destekleyen Kurum
yok
Teşekkür
We thank Esma Özkara from biology department for all help in our study.
Kaynakça
- 1. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020 Jun 4;21(11):4012.
- 2. Gravalos C, Jimeno A. Her2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9): 1523-1529.
- 3. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648.
- 4. Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, et al. Updates on global epidemiology, risk, and prognostic factors of gastric cancer. World J Gastroenterol. 2023 Apr 28;29(16):2452-2468.
- 5. Nemtsova MV, Kuznetsova EB, Bure IV. Chromosomal Instability in Gastric Cancer: Role in Tumor Development, Progression, and Therapy. Int J Mol Sci. 2023 Nov 30;24(23):16961.
- 6. Christodoulidis G, Koumarelas KE, Kouliou MN, Thodou E, Samara M. Gastric Cancer in the Era of Epigenetics. Int J Mol Sci. 2024 Mar 16;25(6):3381.
- 7. Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C et al. EGFR and HER2 exon 20 insertions in solid tumors: from biology to treatment. Nat Rev Clin Oncol. 2022 Jan;19(1):51-69.
- 8. Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer. 2024 Feb;10(2):113-123.
- 9. Okines AF, Cunningham D. Transtuzumab in gastric cancer. Eur J Cancer 2010;46(11): 1949-1959.
- 10. Kang Y, Bang Y, Lordick F, Park SR, Sawaki A, Chung HC, et al. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity 2008 Gastrointestinal Cancers Symposium. 75 (Abstr 11).